Swiftmerge Acquisition Corp. (IVCP) to Combine with HDL Therapeutics in $480M Deal
Swiftmerge (NASDAQ:IVCP) has entered into a definitive agreement to combine with commercial-stage biotech firm HDL Therapeutics at a $480 million valuation.
Vero Beach, Florida-based HDL has developed a medical device designed to remove plaques from patients’ coronary arteries and has been approved for some high-risk patients. ...READ MORE
